PALO ALTO, CA, [28 October 2024] — Lucence, a precision oncology company, today announced that its LiquidHALLMARK® ctDNA and ctRNA liquid biopsy test will now be available to members of multiple Regence health plans across the Pacific Northwest and Intermountain regions. This expansion makes LiquidHALLMARK accessible to more patients who may benefit from its comprehensive genomic profiling capabilities.
Participation includes Regence’s commercial plans as well as Medicare Advantage plans where applicable. Lucence is participating in Regence’s Participating, Preferred, Individual and Family, and RealValue networks for the following :
– Regence BlueCross BlueShield of Oregon
– Regence BlueCross BlueShield of Utah
– Regence BlueShield (Washington)
– Regence BlueShield of Idaho
– Asuris Northwest Health
“We are pleased to expand access to LiquidHALLMARK for Regence members across multiple states,” said Dr. Min-Han Tan, Founding CEO of Lucence. “This coverage decision will allow more patients with advanced cancers to benefit from comprehensive liquid biopsy testing to inform their treatment decisions.”
LiquidHALLMARK is Lucence’s next-generation sequencing liquid biopsy test that analyzes circulating tumor DNA and RNA to detect clinically relevant genomic alterations across multiple cancer types. The test can identify guideline-recommended biomarkers to help oncologists match patients to targeted therapies and clinical trials.
Regence plan members should consult their explanation of benefits or contact Regence customer service to confirm coverage details for LiquidHALLMARK testing. Healthcare providers should review medical policy for guidance regarding coverage for LiquidHALLMARK testing. Providers can find more information about ordering the test at www.lucence.com.
About Lucence
Lucence is a precision oncology company focused on bringing clarity to cancer care. Our ultrasensitive liquid biopsy tests are based on proprietary AmpliMark™ sequencing technology and data analytics for earlier detection and effective treatment. Lucence operates twin CLIA-licensed, CAP-accredited laboratories in California and Singapore. For more information, visit www.lucence.com.